Pfizer
Alexandre de Germay currently serves as the Chief International Commercial Officer at Pfizer since December 2023 and as the Chief Executive Officer at Laboratoires Majorelle since October 2021. Previously, Alexandre held various senior leadership roles at Sanofi from June 2016 to October 2021, including Senior Vice President Global Head of Cardiovascular and Established Products Franchise and Head of General Medicines Business. Alexandre's extensive career at Pfizer from June 1995 to May 2016 encompassed multiple positions such as Regional President Asia-Pacific, Vice President of Global Brands, and Senior Director of Worldwide Commercial Lead for Urology, Gynaecology, and Sexual Health, among others.
This person is not in any offices
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.